 |
|
Oral Antiplatelet Therapy—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Dr Borja correctly points out that triflusal is another antiplatelet drug that has been demonstrated to be effective in vascular disease and was included in the Antithrombotic Trialists’ Collaboration Meta-analysis.1 In addition, triflusal appears to have similar efficacy when compared directly with aspirin in preventing recurrent vascular events in patients with acute MI and TIA or ischemic stroke.2-3 To our knowledge, triflusal is not currently available in North America and Australasia, and therefore it was not included in our critical review of direct comparisons of various antiplatelet regimens. Presumably for similar reasons, triflusal has not been included in the current guidelines from the American College of Chest Physicians.4 We agree that the benefit and safety profile of various antiplatelet therapies may not be of similar magnitude in patients with CAD, TIA/stroke, and peripheral arterial disease. Nevertheless, our recommendations are based on current available evidence. Ongoing trials will hopefully . . . [Full Text of this Article]
Huyen Tran, MBBS, FRACP, FRCPA
Thromboembolism Unit
Sonia S. Anand, MD, PhD, FRCPC
anands@mcmaster.ca
Department of Medicine
Faculty of Health Sciences
McMaster University
Hamilton, Ontario
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Oral Antiplatelet Therapy
Javier Borja
JAMA. 2005;293(7):793.
EXTRACT
| FULL TEXT
Oral Antiplatelet Therapy
Richard A. Bernstein and Gregory W. Albers
JAMA. 2005;293(7):793-794.
EXTRACT
| FULL TEXT
Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease
Huyen Tran and Sonia S. Anand
JAMA. 2004;292(15):1867-1874.
ABSTRACT
| FULL TEXT
|
